Ascendis Pharma A/S

Common Name
Ascendis Pharma
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
Employees
1,017
Ticker
ASND
Exchange
NASDAQ/NGS
Description
Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative drug therapies for unmet medical needs. The company employs its proprietary TransCon technology platform to cre...

Ascendis Pharma's GHG Emissions Data Preview

In 2024, Ascendis Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Ascendis Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Download Data

Verified Sources Behind Ascendis Pharma’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ascendis Pharma’s data sources below and access millions more through our Disclosure Search.

a. Ascendis Pharma's ESG Report 2024
a. Ascendis Pharma's ESG Report 2024

Insights into Ascendis Pharma's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Ascendis Pharma amounted to 1,109 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Ascendis Pharma's Scope 1 Emissions Over Time

2024020406080tCO2e
  • Total Scope 1
  • Year-over-Year Change

What are Ascendis Pharma's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Ascendis Pharma were 62 metric tons of CO₂ equivalent (tCO₂e). a

What are Ascendis Pharma's Scope 2 emissions?

In 2024, Ascendis Pharma reported Scope 2 greenhouse gas (GHG) emissions of 672 tCO₂e using the market-based method and 1,047 tCO₂e using the location-based method. a

What methodology does Ascendis Pharma use for Scope 2 reporting?

In 2024, Ascendis Pharma reported its Scope 2 emissions using the market-based method and using the location-based method. a

Ascendis Pharma's Scope 2 Emissions Over Time

202403006009001.2 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Ascendis Pharma’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Ascendis Pharma reported Scope 1 greenhouse gas (GHG) emissions of 62 tCO₂e and total revenues of USD 443 millions. This translates into an emissions intensity of 0.14 tCO₂e per millions USD. a

Ascendis Pharma's Scope 1 Emissions Intensity Compared to Peers

5501,00010,000100,000Scope 1 Emissions (tCO2e)5505005,000100,000Revenues (Millions of USD)AGenmabYear: 2024Scope 1: 534 tCO2eRevenue: $M 3,003Scope 1 Intensity: 0.18 tCO2e/$MInnoCare PharmaYear: 2023Scope 1: 20 tCO2eRevenue: $M 104Scope 1 Intensity: 0.19 tCO2e/$MPharma MarYear: 2023Scope 1: 1,233 tCO2eRevenue: $M 175Scope 1 Intensity: 7.04 tCO2e/$MBio-TechneYear: 2023Scope 1: 3,001 tCO2eRevenue: $M 1,137Scope 1 Intensity: 2.64 tCO2e/$MShanghai Henlius BiotechYear: 2023Scope 1: 6,909 tCO2eRevenue: $M 830Scope 1 Intensity: 8.32 tCO2e/$MRemeGenYear: 2024Scope 1: 54 tCO2eRevenue: $M 234Scope 1 Intensity: 0.23 tCO2e/$MIdorsiaYear: 2024Scope 1: 733 tCO2eRevenue: $M 124Scope 1 Intensity: 5.90 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MLegend BiotechYear: 2024Scope 1: 769 tCO2eRevenue: $M 627Scope 1 Intensity: 1.23 tCO2e/$MGenscript BiotechYear: 2024Scope 1: 39,377 tCO2eRevenue: $M 4,637Scope 1 Intensity: 8.49 tCO2e/$MShanghai Junshi BiosciencesYear: 2024Scope 1: 5,308 tCO2eRevenue: $M 267Scope 1 Intensity: 19.88 tCO2e/$MBavarian NordicYear: 2023Scope 1: 4,364 tCO2eRevenue: $M 1,046Scope 1 Intensity: 4.17 tCO2e/$MALK-AbelloYear: 2023Scope 1: 10,256 tCO2eRevenue: $M 714Scope 1 Intensity: 14.36 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 2,027Scope 1 Intensity: 1.42 tCO2e/$MAkesoYear: 2024Scope 1: 6,408 tCO2eRevenue: $M 318Scope 1 Intensity: 20.17 tCO2e/$MSK BiopharmaceuticalsYear: 2024Scope 1: 414 tCO2eRevenue: $M 373Scope 1 Intensity: 1.11 tCO2e/$MSK BioscienceYear: 2023Scope 1: 5,863 tCO2eRevenue: $M 289Scope 1 Intensity: 20.28 tCO2e/$MAAAurisco PharmaceuticalYear: 2024Scope 1: 2,731 tCO2eRevenue: $M 202Scope 1 Intensity: 13.51 tCO2e/$MGubraYear: 2023Scope 1: 6 tCO2eRevenue: $M 30Scope 1 Intensity: 0.20 tCO2e/$MCamurusYear: 2024Scope 1: 116 tCO2eRevenue: $M 169Scope 1 Intensity: 0.68 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MBeOne MedicinesYear: 2024Scope 1: 3,547 tCO2eRevenue: $M 27,369Scope 1 Intensity: 0.13 tCO2e/$MAsymchem Laboratories (Tianjin)Year: 2023Scope 1: 46,854 tCO2eRevenue: $M 1,101Scope 1 Intensity: 42.55 tCO2e/$MZealand PharmaYear: 2024Scope 1: 145 tCO2eRevenue: $M 9Scope 1 Intensity: 16.60 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$M

How does Ascendis Pharma's GHG emissions intensity compare to its peers?

In 2024, Ascendis Pharma reported a Scope 1 emissions intensity of 0.14 tCO₂e per millions USD. Compared to the peer group median of 4.58 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a

Where does Ascendis Pharma rank on GHG emissions intensity within its industry?

In 2024, Ascendis Pharma ranked 2 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

This places Ascendis Pharma among the top performers, with one of the lowest emissions intensities relative to peers. a

Want Full Access to Ascendis Pharma's GHG Emissions Dataset?
Sign Up